Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Status:
Not yet recruiting
Trial end date:
2028-02-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472
administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants
with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.
There is no primary hypothesis to be tested for this study.